Navigation Links
Shire Supports Rare Disease Day 2010

CAMBRIDGE, Massachusetts and BASINGSTOKE, England, March 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced it will actively support Rare Disease Day across the world by generating media coverage in many countries to raise awareness and understanding of rare diseases.

Rare Disease Day seeks to call attention to rare diseases as a public health issue, and to reinforce the increased need for access to information, research and treatment. It is coordinated at the international level by European Organisation for Rare Diseases (EURORDIS) and by the National Organization for Rare Disorders (NORD) in the US.

It is estimated that there are between 5,000 and 8,000 known rare diseases affecting 250 million people in the world. Shire has commercially approved and available treatments for Fabry disease, Hereditary Angioedema (HAE) and Hunter syndrome. In addition, Shire expects the U.S. Food & Drug Administration (FDA) to issue its decision for VPRIVTM (velaglucerase alfa for injection), Shire's investigational enzyme replacement treatment for Type 1 Gaucher disease, by February 28.

"For many patients and their families, the journey to a diagnosis and subsequent treatment can be a long, complicated process," said Sylvie Gregoire, President of Shire Human Genetic Therapies (HGT). "Shire is committed to enabling people with life-altering conditions to lead better lives - and for us, this includes improving access to information as well as providing much-needed treatment for rare diseases."

    Shire's Global Rare Disease Day Initiatives include:

    - Extending (, its
    online resource center that aims to connect patients with each other and
    to provide important information about rare diseases.

    - Supporting the Global Genes Project (
    , a grassroots effort to use denim jeans to raise global awareness of
    rare genetic disorders.

    - Supporting its non-profit partners as they visit Capitol Hill to
    advocate for patients with rare diseases in Washington, D.C.,

    - Co-sponsoring with FEDER (Spanish Federation for Rare Diseases) the
    Annual Running Race for Rare Disease Day in Madrid, Spain.

    - Organizing a special walk on February 28th in Brazil to raise awareness
    of rare diseases in the country. It is expected that more than 20 patient
    organizations and their members will participate.

    For the full press release please visit
    Media Contact
    Jessica Mann (Rest of the World) +44(0)1256-894-280

    Jessica Cotrone (North America, HGT) +1-617-613-4640

SOURCE Shire Pharmaceutical

Back to top
SOURCE Shire Pharmaceutical
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
(Date:11/27/2015)... Pittsburgh, PA (PRWEB) , ... November 27, 2015 ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, ... analytical chemistry and applied spectroscopy, covers a wide range of applications such as, ...
(Date:11/25/2015)... India , November 26, 2015 ... The Global Biobanking Market 2016 - 2020 report ... by maintaining integrity and quality in long-term samples, ... enabling long-term cost-effectiveness. Automation minimizes manual errors such ... the technical efficiency. Further, it plays a vital ...
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, Inc. ... participate in a fireside chat discussion at the Piper ... York . The discussion is scheduled for Wednesday, ... .  A replay will be available for ... Stilwell  , Julie NormartVP, Corporate Communications and Business ...
Breaking Biology Technology:
(Date:10/29/2015)... Mich. , Oct. 29, 2015  Rubicon ... Genomics for U.S. distribution of its DNA library ... kit and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX ... enable the preparation of NGS libraries for liquid ... for diagnostic and prognostic applications in cancer and ...
(Date:10/27/2015)... -- In the present market scenario, security is one ... verticals such as banking, healthcare, defense, electronic gadgets, and ... secure & simplified access control and growing rate of ... bank accounts, misuse of users, , and so on. ... and smartphones are expected to provide potential opportunities for ...
(Date:10/26/2015)... and LAS VEGAS , ... Nok Labs , an innovator in modern authentication and ... today announced the launch of its latest version of ... platform enabling organizations to use standards-based authentication that supports ... Nok S3 Authentication Suite is ideal for organizations deploying ...
Breaking Biology News(10 mins):